Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2026)

Adaptive Biotechnologies has disclosed Net Cash Flow across 9 years of filings, most recently posting $7.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $7.1 million, up 179.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 229.24% YoY), and the FY2025 annual result was $22.4 million, up 230.2% from the prior year.
• Net Cash Flow came in at $7.1 million for Q1 2026 at Adaptive Biotechnologies, down from $15.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $141.1 million in Q3 2022 to a low of -$127.6 million in Q4 2022.
• The 5-year median for Net Cash Flow is $2.5 million (2025), against an average of -$3.6 million.
• Peak annual rise in Net Cash Flow reached 328.42% in 2022, while the deepest fall reached 865.46% in 2022.
• Adaptive Biotechnologies' Net Cash Flow stood at -$127.6 million in 2022, then soared by 81.47% to -$23.6 million in 2023, then surged by 141.27% to $9.8 million in 2024, then jumped by 58.49% to $15.5 million in 2025, then sank by 54.04% to $7.1 million in 2026.
• The last three Net Cash Flow figures came in at $7.1 million (Q1 2026), $15.5 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.